WO2005023243A1 - The combination of a serotonin reuptake inhibitor and loxapine - Google Patents
The combination of a serotonin reuptake inhibitor and loxapine Download PDFInfo
- Publication number
- WO2005023243A1 WO2005023243A1 PCT/DK2004/000581 DK2004000581W WO2005023243A1 WO 2005023243 A1 WO2005023243 A1 WO 2005023243A1 DK 2004000581 W DK2004000581 W DK 2004000581W WO 2005023243 A1 WO2005023243 A1 WO 2005023243A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- serotonin
- serotonin reuptake
- reuptake inhibitor
- compound
- pharmaceutically acceptable
- Prior art date
Links
- YNENCIAHZZPEMP-UHFFFAOYSA-N COc1cccc(C2CCCN(CC3)CCC3c3cc(Cl)ccc3)c1CCC2O Chemical compound COc1cccc(C2CCCN(CC3)CCC3c3cc(Cl)ccc3)c1CCC2O YNENCIAHZZPEMP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to the use of a combination of Loxapine and a serotonin reuptake inhibitor (SRI), or any other compound, which causes an elevation in the level of extracellular serotonin, for the treatment of depression and other affective disorders.
- SRI serotonin reuptake inhibitor
- SSRIs Selective serotonin reuptake inhibitors
- Augmentation of antidepressant therapy may be accomplished through the co- administration of mood stabilizers such as lithium carbonate or triiodothyronin or by the use of electroshock.
- Loxapine or pharmaceutically acceptable salts thereof may be used to augment and provide faster onset of the therapeutic effect of serotonin reuptake inhibitors.
- the invention relates to use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
- the invention relates to use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
- the invention relates to a pharmaceutical composition or kit comprising Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, and optionally pharmaceutically acceptable carriers or diluents.
- the invention relates to a method for the treatment of diseases or disorders responsive to a serotonin reuptake inhibitor or any other compound which causes an elevation in the level of extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor, or a compound which causes an elevation in the level of extracellular serotonin, to an individual in need thereof.
- the invention relates to use of Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, for the preparation of a pharmaceutical composition for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor or any other compound causing an elevation in the level of extracellular serotonin.
- the invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, for the preparation of a kit for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor or any other compound causing an elevation in the level of extracellular serotonin.
- the invention relates to a method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof to an individual to be treated with or undergoing treatment with the serotonin reuptake inhibitor, or any other compound which causes an elevation in the level of extracellular serotonin.
- the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder and drug abuse, in particular depression.
- the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of anxiety disorders including general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
- the serotonin reuptake inhibitor or the compound which causes an elevation in the level of extracellular serotonin is used in the treatment of psychoses, including schizophrenia and schizoaffective disorders.
- the serotonin reuptake inhibitor is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine or a pharmaceutically acceptable salt of any of these compounds.
- citalopram escitalopram
- fluoxetine sertraline
- paroxetine fluvoxamine
- venlafaxine venlafaxine
- dapoxetine nefazodone
- imipramin femoxetine and clomipramine
- each of the serotonin reuptake inhibitors specified above is intended to be an individual embodiment. Accordingly, each of them and the use thereof may be claimed individually.
- the serotonin reuptake inhibitor is escitalopram.
- the serotonin reuptake inhibitor is citalopram.
- the serotonin reuptake inhibitor is a selective serotonin reuptake inhibitor (SSRI).
- SSRI selective serotonin reuptake inhibitor
- composition or kit prepared is adapted for simultaneous administration of the active ingredients.
- active ingredients are contained in the same unit dosage form.
- composition or kit prepared is adapted for sequential administration of the active ingredients.
- active ingredients are contained in discrete unit dosage forms.
- the present invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition to be used in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
- the present invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition useful for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
- the present invention relates to the use as above, of Loxapine, or a pharmaceutically acceptable salt thereof, for the treatment of depression, anxiety disorders and other affective disorders, such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, psychosis including schizophrenia and schizoaffective disorders and drug abuse, in particular depression, in combination with a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
- affective disorders such as generalized anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post traumatic stress disorder and social anxiety disorder eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders
- the anxiety disorders mentioned above include general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
- augmenting covers improving the therapeutic effect and/or potentiating the therapeutic effect of an SRI or a compound which causes an elevation in the level of extracellular 5-HT.
- the invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level of extracellular serotonin, for the preparation of a pharmaceutical composition for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor, or any other compound, which causes an elevation in the level of extracellular serotonin.
- the invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level of extracellular serotonin, for the preparation of a kit-of-parts (kit) for the treatment of diseases or disorders responsive to the therapeutic effect of a serotonin reuptake inhibitor, or any other compound, which causes an elevation in the level of extracellular serotonin.
- kit-of-parts kit-of-parts
- the diseases responsive to a serotonin reuptake inhibitor include depression, anxiety disorders and other affective disorders, eating disorders such as bulimia, anorexia and obesity, phobias, dysthymia, premenstrual syndrome, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, psychosis, including schizophrenia and schizoaffective disorders, psychosis, including schizophrenia and schizoaffective disorders and drug abuse, in particular depression.
- anxiety disorders is as defined above.
- the present invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition as above, which is adapted for simultaneous administration of the active ingredients.
- a pharmaceutical composition as above, which is adapted for simultaneous administration of the active ingredients.
- such pharmaceutical compositions may contain the active ingredients within the same unit dosage form, e.g. in the same tablet or capsule.
- Such unit dosage forms may contain the active ingredients as a homogenous mixture or in separate compartments of the unit dosage form.
- the present invention relates to the use of Loxapine or a pharmaceutically acceptable salt thereof for the preparation of a pharmaceutical composition or kit as above, which is adapted for sequential administration of the active ingredients.
- such pharmaceutical compositions may contain the active ingredients in discrete unit dosage forms, e.g. discrete tablets or capsules containing either of the active ingredients. These discrete unit dosage forms may be contained in the same container or package, e.g. a blister pack.
- kit means a pharmaceutical composition containing each of the active ingredients, but in discrete unit dosage forms.
- the invention also relates to a pharmaceutical composition or kit comprising Loxapine or a pharmaceutically acceptable salt thereof and a compound, which is a serotonin reuptake inhibitor, or any other compound, which causes an elevation in extracellular 5-HT, and optionally pharmaceutically acceptable carriers or diluents.
- the pharmaceutical composition or kit of the invention may be adapted for simultaneous administration of the active ingredients or for sequential administration of the active ingredients, as described above.
- the present invention relates to a method for the treatment of diseases or disorders responsive to a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof and a serotonin reuptake inhibitor, or a compound, which causes an elevation in the level of extracellular serotonin, to an individual in need thereof.
- the present invention relates to a method for augmenting and/or providing faster onset of the therapeutic effect of a serotonin reuptake inhibitor or any other compound, which causes an elevation in the level extracellular serotonin, comprising administering Loxapine or a pharmaceutically acceptable salt thereof to an individual to be treated with or undergoing treatment with the serotonin reuptake inhibitor or any other compound, which causes an elevation in the level of extracellular serotonin.
- the individuals which may benefit from treatment with a combination as above, may suffer from depression, anxiety disorders and other affective disorders, psychosis, eating disorders such as bulimia, anorexia and obesity, phobias, premenstrual syndrome, dysthymia, cognitive disorders, impulse control disorders, attention deficit hyperactivity disorder, psychosis, and drug abuse, in particular depression.
- anxiety disorder includes general anxiety disorder, panic anxiety, obsessive compulsive disorder, acute stress disorder, post trauma stress disorder or social anxiety disorder.
- Psychosis includes but is not limited to schizophrenia and schizoaffective disorders.
- Loxapine and the serotonin reuptake inhibitor may be administered simultaneously as described above.
- the active ingredients may be administered sequentially, e.g. in two discrete unit dosage forms as described above.
- serotonin reuptake inhibitors show delayed onset of action. Even in responders to SSRIs, several weeks of treatment are necessary to achieve a relief in symptoms. Loxapine may provide fast onset of therapeutic effect of serotonin reuptake inhibitors.
- the use of a combination of Loxapine and a serotonin reuptake inhibitor may greatly reduce the amount of serotonin reuptake inhibitor necessary to treat depression and other affective disorders and may thus reduce the side effects caused by the serotonin reuptake inhibitor.
- the combination of a reduced amount of SRI and Loxapine may reduce the risk of SSRI-induced sexual dysfunction and sleep disturbances.
- Co-administration of Loxapine and a serotonin reuptake inhibitor may also be useful for the treatment of refractory depression, i.e. depression, which cannot be treated appropriately by administration of a serotonin reuptake inhibitor alone.
- Loxapine may be used as add-on therapy for the augmentation of the response to SRIs in patients where at least 40-60% reduction in symptoms has not been achieved during the first 6 weeks of treatment with an SRI.
- the following list contains a number of serotonin reuptake inhibitors, which may benefit from augmentation with Loxapine: citalopram, escitalopram, fluoxetine, R-fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, duloxetine, dapoxetine, nefazodone, imipramine, imipramine N-oxide, desipramine, pirandamine, dazepinil, nefopam, befuraline, fezolamine, femoxetine, clomipramine, cianoimipramine, litoxetine, cericlamine, seproxetine, WY 27587, WY 27866, imeldine, ifoxetine, tiflucarbine, viqualine, milnacipran, apelinaprine, YM 922, S 33005, F 98214-TA, OPC 14523, alaproclate, cyano
- compounds such as citalopram, escitalopram, fluoxetine, R-fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, desmethylvenlafaxine, duloxetine, dapoxetine, vilazodone, nefazodone, imipramine, imipramine N-oxide, desipramine, pirandamine, dazepinil, nefopam, befuraline, fezolamine, femoxetine, clomipramine, cianoimipramine, litoxetine, cericlamine, seproxetine, imeldine, ifoxetine, indeloxazine, tiflucarbine, viqualine, milnacipran, apelinaprine, alaproclate, cyanodothepine, trimipramine, quinupramine, dothiepin, Loxapine, nitroxazepine, roxindole
- SRIs are suitable as SRIs.
- the compounds mentioned above may be used in the form of the base or a pharmaceutically acceptable acid addition salt thereof.
- Each of the serotonin reuptake inhibitors specified above is intended to be an individual embodiment. Accordingly, each of them and the use thereof may be claimed individually.
- Other therapeutic compounds which may benefit from augmentation with Loxapine include compounds, which causes an elevation in the extracellular level of 5-HT in the synaptic cleft, although they are not serotonin reuptake inhibitors.
- One such compound is tianeptine.
- the above list of serotonin reuptake inhibitors and other compounds, which causes an increase in the extracellular level of serotonin, may not be construed as limiting.
- the SRIs is selected from citalopram, escitalopram, fluoxetine, sertraline, paroxetine, fluvoxamine, venlafaxine, dapoxetine, nefazodone, imipramin, femoxetine and clomipramine.
- citalopram escitalopram
- fluoxetine sertraline
- paroxetine fluvoxamine
- venlafaxine venlafaxine
- dapoxetine nefazodone
- imipramin femoxetine
- clomipramine imipramin
- each of these SRIs constitute individual embodiments, and may be the subject of individual claims.
- SSRI selective serotonin reuptake inhibitor
- SRIs selective serotonin reuptake inhibitors
- SSRIs selective serotonin reuptake inhibitors
- the SRI is selected from SSRIs, such as citalopram, escitalopram, fluoxetine, fluvoxamine, sertraline or paroxetine.
- the active ingredients according to the invention i.e. Loxapine and the SRI or a compound causing an increase in extracellular serotonin levels, may be used in the free base form or in the form of a pharmaceutically acceptable acid addition salt thereof, the latter being obtainable by reaction of the base form with an appropriate acid.
- Citalopram is preferably used in the form of the hydrobromide or as the base, escitalopram in the form of the oxalate, fluoxetine, sertraline and paroxetine in the form of the hydrochloride and fluvoxamine in the form of the maleate.
- the combination of Loxapine with a serotonin reuptake inhibitor unexpectedly shows a synergistic effect on the central nervous system (CNS).
- CNS central nervous system
- combination therapy using Loxapine and lower doses of the serotonin reuptake inhibitor than normally used in monotherapy may be effective, and side-effects associated with the larger amounts of serotonin reuptake inhibitor used in monotherapy may be reduced or prevented altogether.
- combination therapy with Loxapine using a normal dose of serotonin reuptake inhibitor has the advantage that an effective CNS effect may be obtained in the often large number of patients who do not respond to conventional monotherapy with SSRIs.
- the amount of Loxapine used in combination therapy may range from about 0.001 to about 1 g/day, such as from about 0.001 to about 0.1 mg/day, about 0.1 to about 1 mg/day, about 1 mg/day to about 10 mg/day, about 10 mg/day to about 100 mg/day and from about 100 mg/day to about 1 g/day.
- Serotonin reuptake inhibitors differ both in molecular weight and in activity. As a consequence, the amount of serotonin reuptake inhibitor used in combination therapy depends on the nature of said serotonin reuptake inhibitor.
- the serotonin reuptake inhibitor or the compound causing an increase in the level of extracellular 5-HT is administered at lower doses than required when the compound is used alone. In another embodiment, the serotonin reuptake inhibitor or the compound causing an increase in the level of extracellular 5-HT, is administered in normal doses.
- compositions of this invention an appropriate amount of the active ingredient(s), in salt form or base form, is combined in an intimate admixture with a pharmaceutically acceptable carrier, which can take a wide variety of forms depending on the form of preparation desired for administration.
- a pharmaceutically acceptable carrier which can take a wide variety of forms depending on the form of preparation desired for administration.
- These pharmaceutical compositions are desirably in unitary dosage form suitable for administration orally, rectally, percutaneously or by parenteral injection.
- any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils, alcohols and the like in the case of oral liquid preparations such as suspensions, syrups, elixirs and solutions; or solid carriers such as starches, sugars, kaolin, lubricants, binders, disintegrating agents and the like in the case of powders, pills, capsules and tablets.
- solid pharmaceutical carriers are obviously employed. It is especially advantageous to formulate the aforementioned pharmaceutical compositions in dosage unit form for ease of administration and uniformity of dosage.
- unit dosage form refers to physically discrete units suitable as unitary dosages, each unit containing a predetermined quantity of active ingredient(s) calculated to produce the desired therapeutic effect, in association with the required pharmaceutical carrier.
- dosage unit forms are tablets (including scored or coated tablets), capsules, pills, powder packets, wafers, injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated multiples thereof.
- Loxapine may be admimstered before, during or after the administration of the serotonin reuptake inhibitor provided that the time between the administration of Loxapine and the administration of the serotonin reuptake inhibitor is such that ingredients are allowed to act synergistically on the CNS.
- a composition containing both a serotonin reuptake inhibitor and Loxapine may be particularly convenient.
- Loxapine and the serotonin reuptake inhibitor may be administered separately in the form of suitable compositions.
- the compositions may be prepared as described hereinabove.
- the present invention also comprises products containing Loxapine and a serotonin reuptake inhibitor as a combination preparation for simultaneous, separate or sequential use in psychiatric drug therapy.
- Such products may comprise, for example, a kit comprising discrete unit dosage forms containing Loxapine and discrete unit dosage forms containing a serotonin reuptake inhibitor, all contained in the same container or pack, e.g. a blister pack.
- preparations for simultaneous or sequential administration may instead of a serotonin reuptake inhibitor contain another compound causing an elevation in the level of extracellular 5-HT.
- mice Male albino rats of a Wistar-derived strain (285-320 g; Harlan, Zeist, The Netherlands) were used for the experiments. Upon surgery, rats were housed individually in plastic cages (35 x 35 x 40 cm), and had free access to food and water. Animals were kept on a 12 h light schedule (light on 7:00 a.m.). The experiments are concordant with the declarations of Helsinki and were approved by the animal care committee of the faculty of mathematics and natural science of the University of Groningen.
- escitalopram oxalate and loxapine (Lundbeck A S, Copenhagen, Denmark)
- Microdialysis of brain serotonin levels was performed using home made I-shaped probes, made of polyacrylonitrile / sodium methyl sulfonate copolymer dialysis fiber (i.d. 220 ⁇ m, o.d. 0.31 ⁇ m, AN 69, Hospal, Italy).
- Preceding surgery rats were anaesthetised using isoflurane (O 2 /N 2 O; 300/300ml/min). Lidocaine-HCl, 10 % (m v) was used for local anaesthesia.
- Rats were placed in a stereotaxic frame (Kopf, USA), and probes were inserted into Ventral Hippocampus (V. Hippo, L +4.8 mm, IA: +3.7 mm, V: -8.0 mm) (Paxinos and Watson, 1982). After insertion, probes were secured with dental cement.
- Rats were allowed to recover for at least 24 h. Probes were perfused with artificial cerebrospinal fluid containing 147 mM NaCl, 3.0 mM KC1, 1.2 mM CaCl 2 , and 1.2 mM MgCl 2 , at a flow-rate of 1.5 ⁇ l / min (Harvard apparatus, South Natick, Ma., USA). 15 minute microdialysis samples were collected in HPLC vials containing 7.5 ⁇ l 0.02 M acetic acid for serotonin analysis.
- 5- HT was detected amperometrically at a glassy carbon electrode at 500 mV vs Ag/AgCl (Antec Leyden, Leiden, The Netherlands). The detection limit was 0.5 frnol 5-HT per 20 ⁇ l sample (signal to noise ratio 3).
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Addiction (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Child & Adolescent Psychology (AREA)
- Nutrition Science (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Description
Claims
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA200600531A EA200600531A1 (en) | 2003-09-04 | 2004-09-01 | COMBINATION OF SEROTONIN AND LOXAPINE REVERSE CAPTURE INHIBITOR |
US10/570,472 US20070042014A1 (en) | 2003-09-04 | 2004-09-01 | Combination of a serotonin reuptake inhibitor and loxapine |
AU2004269858A AU2004269858A1 (en) | 2003-09-04 | 2004-09-01 | The combination of a serotonin reuptake inhibitor and Loxapine |
CA002537747A CA2537747A1 (en) | 2003-09-04 | 2004-09-01 | The combination of a serotonin reuptake inhibitor and loxapine |
BRPI0413750-7A BRPI0413750A (en) | 2003-09-04 | 2004-09-01 | use of loxapine or a pharmaceutically acceptable salt thereof, pharmaceutical composition, and kit |
JP2006525048A JP2007504181A (en) | 2003-09-04 | 2004-09-01 | Combination of serotonin reuptake inhibitor and loxapine |
EP04762801A EP1670454A1 (en) | 2003-09-04 | 2004-09-01 | The combination of a serotonin reuptake inhibitor and loxapine |
MXPA06002504A MXPA06002504A (en) | 2003-09-04 | 2004-09-01 | The combination of a serotonin reuptake inhibitor and loxapine. |
IS8326A IS8326A (en) | 2003-09-04 | 2006-02-23 | The mixture of serotonin reuptake inhibitor and loxapine |
IL173968A IL173968A0 (en) | 2003-09-04 | 2006-02-27 | The combination of a serotonin reuptake inhibitor and loxapine |
NO20061425A NO20061425L (en) | 2003-09-04 | 2006-03-29 | The combination of a serotonin reuptake inhibitor and loxapine |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US50080903P | 2003-09-04 | 2003-09-04 | |
DKPA200301270 | 2003-09-04 | ||
US60/500,809 | 2003-09-04 | ||
DKPA200301270 | 2003-09-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005023243A1 true WO2005023243A1 (en) | 2005-03-17 |
Family
ID=34276705
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/DK2004/000581 WO2005023243A1 (en) | 2003-09-04 | 2004-09-01 | The combination of a serotonin reuptake inhibitor and loxapine |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1670454A1 (en) |
JP (1) | JP2007504181A (en) |
AU (1) | AU2004269858A1 (en) |
BR (1) | BRPI0413750A (en) |
CA (1) | CA2537747A1 (en) |
MX (1) | MXPA06002504A (en) |
NO (1) | NO20061425L (en) |
WO (1) | WO2005023243A1 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007111983A2 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | New therapeutic combinations for the treatment or prevention of psychotic disorders |
WO2007124757A2 (en) * | 2006-05-02 | 2007-11-08 | H. Lundbeck A/S | Use of escitalopram for improving cognition |
WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
US7671196B2 (en) | 2005-07-26 | 2010-03-02 | Wyeth Llc | Diazepinoquinolines, synthesis thereof, and intermediates thereto |
US7781427B2 (en) | 2004-11-05 | 2010-08-24 | Wyeth Llc | Process for preparing quinoline compounds and products obtained therefrom |
WO2020060252A1 (en) * | 2018-09-21 | 2020-03-26 | 에스케이바이오팜 주식회사 | Use of carbamate compound for prevention, alleviation, or treatment of concurrent seizures |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0958824A2 (en) * | 1998-05-22 | 1999-11-24 | Eli Lilly And Company | Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression |
WO2001051041A1 (en) * | 2000-01-13 | 2001-07-19 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
US20020151543A1 (en) * | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
US20030130266A1 (en) * | 2001-12-14 | 2003-07-10 | Miodrag Radulovacki | Pharmacological treatment for sleep apnea |
-
2004
- 2004-09-01 MX MXPA06002504A patent/MXPA06002504A/en not_active Application Discontinuation
- 2004-09-01 WO PCT/DK2004/000581 patent/WO2005023243A1/en not_active Application Discontinuation
- 2004-09-01 BR BRPI0413750-7A patent/BRPI0413750A/en not_active Application Discontinuation
- 2004-09-01 CA CA002537747A patent/CA2537747A1/en not_active Abandoned
- 2004-09-01 EP EP04762801A patent/EP1670454A1/en not_active Withdrawn
- 2004-09-01 AU AU2004269858A patent/AU2004269858A1/en not_active Abandoned
- 2004-09-01 JP JP2006525048A patent/JP2007504181A/en not_active Withdrawn
-
2006
- 2006-03-29 NO NO20061425A patent/NO20061425L/en not_active Application Discontinuation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0958824A2 (en) * | 1998-05-22 | 1999-11-24 | Eli Lilly And Company | Olanzapine (zyprexa) in combination with fluoxetine (prozac), lithium or anticonvulsant for therapy of refractory depression |
US20020151543A1 (en) * | 1998-05-28 | 2002-10-17 | Sepracor Inc. | Compositions and methods employing R (-) fluoxetine and other active ingredients |
WO2001051041A1 (en) * | 2000-01-13 | 2001-07-19 | Osmotica Corp. | Osmotic device containing venlafaxine and an anti-psychotic agent |
US20030130266A1 (en) * | 2001-12-14 | 2003-07-10 | Miodrag Radulovacki | Pharmacological treatment for sleep apnea |
Non-Patent Citations (9)
Title |
---|
"Table 3. Descriptive data of individuals with OCD and psychosis developing simultaneously", 12 June 2002 (2002-06-12), XP002303141, Retrieved from the Internet <URL:http://www.cpa-apc.org/Publications/Archives/CJP/2001/October/obsess_tab3.html> [retrieved on 20041028] * |
ABDUL AL-MULHIM: "Provocation of ObsessiveCompulsive Behaviour and Tremor by Olanzapine", 28 February 2002 (2002-02-28), XP002303142, Retrieved from the Internet <URL:http://www.cpa-apc.org/Publications/Archives/CJP/1998/Aug/letters2.html> [retrieved on 20041028] * |
AD SITSEN J M ET AL: "The pharmacological treatment of depression and its problems", MEDICAL PSYCHIATRY; HANDBOOK OF DEPRESSION AND ANXIETY: A BIOLOGICAL APPROACH MARCEL DEKKER, INC., 270 MADISON AVENUE, NEW YORK, NEW YORK 10016, USA; MARCEL DEKKER, INC., BASEL, SWITZERLAND SERIES : MEDICAL PSYCHIATRY, 1994, pages 349 - 377, XP001184093, ISSN: 0-8247-8858-3 * |
BONIN B ET AL: "Serotonin syndrome after sertraline, buspirone and loxapine?", THERAPIE (LONDON), vol. 54, no. 2, March 1999 (1999-03-01), pages 269 - 271, XP009039040, ISSN: 0040-5957 * |
DATABASE MEDLINE [online] US NATIONAL LIBRARY OF MEDICINE (NLM), BETHESDA, MD, US; July 2004 (2004-07-01), SÁNCHEZ CONNIE ET AL: "Escitalopram versus citalopram: the surprising role of the R-enantiomer.", XP002303146, Database accession no. NLM15160261 * |
HERRICK-DAVIS K ET AL: "Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.", THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS. OCT 2000, vol. 295, no. 1, October 2000 (2000-10-01), pages 226 - 232, XP002303144, ISSN: 0022-3565 * |
PSYCHOPHARMACOLOGY. JUL 2004, vol. 174, no. 2, July 2004 (2004-07-01), pages 163 - 176, ISSN: 0033-3158 * |
ROTHSCHILD A J ET AL: "Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.", THE JOURNAL OF CLINICAL PSYCHIATRY. SEP 1993, vol. 54, no. 9, September 1993 (1993-09-01), pages 338 - 342, XP009039055, ISSN: 0160-6689 * |
ROTHSCHILD ANTHONY J: "Challenges in the treatment of depression with psychotic features.", BIOLOGICAL PSYCHIATRY. 15 APR 2003, vol. 53, no. 8, 15 April 2003 (2003-04-15), pages 680 - 690, XP002303143, ISSN: 0006-3223 * |
Cited By (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7781427B2 (en) | 2004-11-05 | 2010-08-24 | Wyeth Llc | Process for preparing quinoline compounds and products obtained therefrom |
US7671196B2 (en) | 2005-07-26 | 2010-03-02 | Wyeth Llc | Diazepinoquinolines, synthesis thereof, and intermediates thereto |
WO2007111983A2 (en) * | 2006-03-24 | 2007-10-04 | Wyeth | New therapeutic combinations for the treatment or prevention of psychotic disorders |
WO2007111983A3 (en) * | 2006-03-24 | 2008-05-29 | Wyeth Corp | New therapeutic combinations for the treatment or prevention of psychotic disorders |
WO2007124757A2 (en) * | 2006-05-02 | 2007-11-08 | H. Lundbeck A/S | Use of escitalopram for improving cognition |
WO2007124757A3 (en) * | 2006-05-02 | 2008-07-24 | Lundbeck & Co As H | Use of escitalopram for improving cognition |
WO2008118141A2 (en) * | 2006-10-17 | 2008-10-02 | Acadia Pharmaceuticals Inc. | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
WO2008118141A3 (en) * | 2006-10-17 | 2008-12-24 | Acadia Pharm Inc | Use of cannabinoid modulating compounds in combination with other therapeutic compounds for adjunctive therapy |
WO2020060252A1 (en) * | 2018-09-21 | 2020-03-26 | 에스케이바이오팜 주식회사 | Use of carbamate compound for prevention, alleviation, or treatment of concurrent seizures |
US12070448B2 (en) | 2018-09-21 | 2024-08-27 | Sk Biopharmaceuticals Co., Ltd. | Use of carbamate compound for prevention, alleviation or treatment of status epilepticus |
Also Published As
Publication number | Publication date |
---|---|
NO20061425L (en) | 2006-03-29 |
BRPI0413750A (en) | 2006-10-24 |
JP2007504181A (en) | 2007-03-01 |
AU2004269858A1 (en) | 2005-03-17 |
EP1670454A1 (en) | 2006-06-21 |
MXPA06002504A (en) | 2006-06-20 |
CA2537747A1 (en) | 2005-03-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20100267772A1 (en) | Combination of a Serotonin Reuptake Inhibitor and Agomelatine | |
US20090203731A1 (en) | Treatment of depression and other affective disorders | |
EP2145620A2 (en) | Gaboxadol for treating depression and other affective disorders | |
EP1545552B1 (en) | Combination therapy wherein a serotonin reuptake inhibitor is used | |
WO2005023243A1 (en) | The combination of a serotonin reuptake inhibitor and loxapine | |
US20070042014A1 (en) | Combination of a serotonin reuptake inhibitor and loxapine | |
WO2005056056A2 (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
US20060223857A1 (en) | Combination of a serotonin reuptake inhibitor and a glycine transporter type 1 inhibitor for the treatment of depression | |
US20080167290A1 (en) | Combination of a Serotonin Reuptake Inhibitor and Amoxapine | |
US20070066601A1 (en) | Combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
CA2537757A1 (en) | The combination of a serotonin reuptake inhibitor and amoxapine | |
ZA200509588B (en) | The combination of a serotonin reuptake inhibitors and agomelatine | |
MXPA06005127A (en) | The combination of a serotonin reuptake inhibitor and a histamine 3 receptor antagonist, inverse agonist or partial agonist | |
CA2579520A1 (en) | Combination therapy wherein a serotonin reuptake inhibitor is used |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480025142.8 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 545084 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006/01459 Country of ref document: ZA Ref document number: 200601459 Country of ref document: ZA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 173968 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020067004131 Country of ref document: KR Ref document number: 2006525048 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004269858 Country of ref document: AU Ref document number: 743/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2537747 Country of ref document: CA Ref document number: PA/a/2006/002504 Country of ref document: MX Ref document number: 06021584 Country of ref document: CO |
|
ENP | Entry into the national phase |
Ref document number: 2004269858 Country of ref document: AU Date of ref document: 20040901 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004269858 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004762801 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200600531 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007042014 Country of ref document: US Ref document number: 10570472 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004762801 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020067004131 Country of ref document: KR |
|
ENP | Entry into the national phase |
Ref document number: PI0413750 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10570472 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2004762801 Country of ref document: EP |